COOPERATIVE CLINICAL STUDY ON SSM TREATMENT

• Published in: CHEMOTHERAPY Vol. 28; no. 2; pp. 171 - 177
• Main Authors: HATTORI, TAKANOBU, KOMITA, TERUO, SHIMIZU, YOZO, ARIMORI, SHIGERU, MATSUZAKI, JUN, SATOH, HIROSHI, YAMAMOTO, SHIGERU, FUNASAKA, MOTOKATSU, IRIMAZIRI, NOBUHIRO, ENDO, TAKESHI, UESUGI, KAZUTAKA, KUWABARA, KAZUNORI
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 25.03.1980
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.28.171

Cooperative clinical study was made on the single administration of SSM and on the combined administration of SSM and anticancer chemotherapy drugs (MMC and 5 FU). SSM is an extract from tubercle bacilli of human type, generally called “Maruyama Vaccine” in Japan. SSM is reported that it has host-mediated activity and unique immunotherapeutic agent. We have used SSM in the treatment of 100 patients with advanced cancer. SSM was given by the subcutaneous injection every other day. As to side effect, there were none. Skin testing using PPD and PHA was performed before and during therapy. Thirty-nine patients were initially Mantous negative but conversion to Mantous positive followed SSM therapy. Rate of 48.7% out of patients was responded to PHA stimulation. In the single administration of SSM, only one out of 17 measurable cases showed tumor regression. On the other hand, 13 out of 69 measurable cases of combined treatment showed tumor regression. Such favorable response was seen in the cases of gastric cancer, colon cancer, breast cancer, and others. Life span was examined on 32 gastric cancer patients of combined treatment. One-year survival rate was 28.1% and 2-year survival was 9.4%. Prolongation of life span was seen more markedly on gastric cancer patients of SSM combined treatment than conventional anticancer chemotherapy. This SSM combined with MMC and 5 FU treatment seems to be a promising immunochemotherapy.